Pyrukynd

Chemical Namemitapivat
Dosage FormTablet (oral; 5 mg, 20 mg, 50 mg)
Drug ClassActivators
SystemBlood
CompanyAgios Pharmaceuticals
Approval Year2022

Indication

  • For the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency
Last updated on 4/27/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pyrukynd (mitapivat) Prescribing Information. 2022Agios Pharmaceuticals, Inc., Cambridge, MA
Document TitleYearSource
Mitapivat versus placebo for pyruvate kinase deficiency. 2022New England Journal of Medicine